123 related articles for article (PubMed ID: 28720310)
21. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
[TBL] [Abstract][Full Text] [Related]
22. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
23. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments.
Kesari S
Semin Oncol; 2011 Dec; 38 Suppl 4():S2-10. PubMed ID: 22078644
[TBL] [Abstract][Full Text] [Related]
24. The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins.
Wadehra M; Goodglick L; Braun J
Mol Biol Cell; 2004 May; 15(5):2073-83. PubMed ID: 14978215
[TBL] [Abstract][Full Text] [Related]
25. The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma.
Aderetti DA; Hira VVV; Molenaar RJ; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):346-354. PubMed ID: 29684521
[TBL] [Abstract][Full Text] [Related]
26. Glioblastoma and stem cells.
Altaner C
Neoplasma; 2008; 55(5):369-74. PubMed ID: 18665745
[TBL] [Abstract][Full Text] [Related]
27. The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma.
Chang L; Zhang P; Zhao D; Liu H; Wang Q; Li C; Du W; Liu X; Zhang H; Zhang Z; Jiang C
Tumour Biol; 2016 Mar; 37(3):3979-86. PubMed ID: 26482617
[TBL] [Abstract][Full Text] [Related]
28. The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma.
Li CF; Wu WJ; Wu WR; Liao YJ; Chen LR; Huang CN; Li CC; Li WM; Huang HY; Chen YL; Liang SS; Chow NH; Shiue YL
Oncotarget; 2015 Apr; 6(11):9220-39. PubMed ID: 25940704
[TBL] [Abstract][Full Text] [Related]
29. Accessibilome of human glioblastoma: collagen-VI-alpha-1 is a new target and a marker of poor outcome.
Turtoi A; Blomme A; Bianchi E; Maris P; Vannozzi R; Naccarato AG; Delvenne P; De Pauw E; Bevilacqua G; Castronovo V
J Proteome Res; 2014 Dec; 13(12):5660-9. PubMed ID: 25325876
[TBL] [Abstract][Full Text] [Related]
30. A novel treatment for glioblastoma: integrin inhibition.
Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
[TBL] [Abstract][Full Text] [Related]
31. Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na
Ono Y; Chiba S; Yano H; Nakayama N; Saio M; Tsuruma K; Shimazawa M; Iwama T; Hara H
Biochem Biophys Res Commun; 2016 Dec; 481(1-2):7-12. PubMed ID: 27836549
[TBL] [Abstract][Full Text] [Related]
32. Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab.
Patel KS; Kejriwal S; Thammachantha S; Duong C; Murillo A; Gordon LK; Cloughesy TF; Liau L; Yong W; Yang I; Wadehra M
Neurooncol Adv; 2020; 2(1):vdaa112. PubMed ID: 33063013
[TBL] [Abstract][Full Text] [Related]
33. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity.
Wang CX; Wadehra M; Fisk BC; Goodglick L; Braun J
Blood; 2001 Jun; 97(12):3890-5. PubMed ID: 11389031
[TBL] [Abstract][Full Text] [Related]
34. Glioblastoma cancer stem cells--from concept to clinical application.
Stopschinski BE; Beier CP; Beier D
Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828
[TBL] [Abstract][Full Text] [Related]
35. Basic and Translational Advances in Glioblastoma.
Piccirillo SGM; Alonso MM; Pasqualetti F
Biomed Res Int; 2018; 2018():1820345. PubMed ID: 29780818
[No Abstract] [Full Text] [Related]
36. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
37. Epithelial Membrane Protein-2 in Human Proliferative Vitreoretinopathy and Epiretinal Membranes.
Telander DG; Yu AK; Forward KI; Morales SA; Morse LS; Park SS; Gordon LK
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3112-7. PubMed ID: 27294805
[TBL] [Abstract][Full Text] [Related]
38. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
39. [System biological approach to research and treatment of brain tumors].
Shiraishi T; Tabuchi K; Kotani S; Konagaya A
Tanpakushitsu Kakusan Koso; 2003 Jun; 48(7):795-801. PubMed ID: 12795192
[No Abstract] [Full Text] [Related]
40. Individualized targeted therapy for glioblastoma: fact or fiction?
Weller M; Stupp R; Hegi M; Wick W
Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
